Chinese Market Becomes More Intense for Antidiabetic Drugs

China is currently the country with the largest number of diabetes patients. More and more antidiabetic drugs enter China's centralized procurement with sharply-lowered prices to contend for the market.
by Grace Wang Mar 08, 2021

China's fourth round of national centralized drug procurement has begun, according to Jinfu Chen, deputy head of the National Healthcare Security Administration (NHSA) in Beijing on Jan. 29, 2021. This time five new diabetes medications are included in the procurement list. They are empagliflozin, canagliflozin, repaglinide, nateglinide, and gliclazide.

Grace Wang
ChemLinked Regulatory Analyst
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact